Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13248079 | 0.74 | LMNA (0.62) | LMNACES2CCNT1CDK9TRPV3 | |
| SCHEMBL13906350 | 0.73 | TBK1 (0.37) | LMNACCNT1CDK9TRPV3 | |
| SCHEMBL24783009 | 0.71 | LMNA (0.40) | LMNACES2TRPV3 | |
| SCHEMBL12603760 | 0.71 | TRPV3 (0.38) | LMNACES2CCNT1CDK9TRPV3 | |
| SCHEMBL13370662 | 0.69 | NOS3 (0.35) | LMNACES2 | |
| SCHEMBL14838698 | 0.69 | — | — | |
| SCHEMBL9845773 | 0.69 | LMNA (0.34) | LMNACES2 | |
| SCHEMBL12519550 | 0.69 | LMNA (0.38) | LMNACES2TRPV3 | |
| SCHEMBL16647717 | 0.69 | CES2 (0.47) | LMNACES2TRPV3 | |
| SCHEMBL6360983 | 0.69 | LMNA (0.35) | LMNACES2CCNT1CDK9TRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021226629-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | LMNA 3964/4885CES2 967/4885CCNT1 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.